Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 43

1.

Challenges Across the HIV Care Continuum for Patients With HIV/1 TB Co-infection in Atlanta, GA.

Schechter MC, Bizune D, Kagei M, Holland DP, Del Rio C, Yamin A, Mohamed O, Oladele A, Wang YF, Rebolledo PA, Ray SM, Kempker RR.

Open Forum Infect Dis. 2018 Mar 21;5(4):ofy063. doi: 10.1093/ofid/ofy063. eCollection 2018 Apr.

2.

Growing the Soft Robotics Community Through Knowledge-Sharing Initiatives.

Holland DP, Berndt S, Herman M, Walsh CJ.

Soft Robot. 2018 Apr;5(2):119-121. doi: 10.1089/soro.2018.29013.dph. No abstract available.

PMID:
29648950
3.

Time to Sputum Culture Conversion and Treatment Outcomes Among Patients with Isoniazid-Resistant Tuberculosis in Atlanta, Georgia.

Schechter MC, Bizune D, Kagei M, Machaidze M, Holland DP, Oladele A, Wang YF, Rebolledo PA, Ray SM, Kempker RR.

Clin Infect Dis. 2017 Nov 13;65(11):1862-1871. doi: 10.1093/cid/cix686.

PMID:
29020173
4.

Homeless shelter context and tuberculosis illness experiences during a large outbreak in Atlanta, Georgia.

Connors WJ, Hussen SA, Holland DP, Mohamed O, Andes KL, Goswami ND.

Public Health Action. 2017 Sep 21;7(3):224-230. doi: 10.5588/pha.17.0040.

5.

Outbreak of Drug-Resistant Mycobacterium tuberculosis Among Homeless People in Atlanta, Georgia, 2008-2015.

Powell KM, VanderEnde DS, Holland DP, Haddad MB, Yarn B, Yamin AS, Mohamed O, Sales RF, DiMiceli LE, Burns-Grant G, Reaves EJ, Gardner TJ, Ray SM.

Public Health Rep. 2017 Mar/Apr;132(2):231-240. doi: 10.1177/0033354917694008.

6.

Hepatitis C Virus Postexposure Prophylaxis in the Healthcare Worker: Why Direct-Acting Antivirals Don't Change a Thing.

Naggie S, Holland DP, Sulkowski MS, Thomas DL.

Clin Infect Dis. 2017 Jan 1;64(1):92-99. Epub 2016 Sep 28. Review.

7.

Tackling the unknowns of short-course rifapentine-based treatment for active tuberculosis: a decision analysis.

Holland DP, Hamilton CD, Stout JE.

Int J Tuberc Lung Dis. 2016 Jun;20(6):827-31. doi: 10.5588/ijtld.15.0006.

PMID:
27155188
8.

Medium matters: modeling the impact of solid medium performance on tuberculosis trial sample size requirements.

Johnson MG, Stout JE, Benator DA, Whitworth WC, Holland DP.

Int J Tuberc Lung Dis. 2016 May;20(5):600-4. doi: 10.5588/ijtld.15.0570.

9.

Three months of weekly rifapentine plus isoniazid is less hepatotoxic than nine months of daily isoniazid for LTBI.

Bliven-Sizemore EE, Sterling TR, Shang N, Benator D, Schwartzman K, Reves R, Drobeniuc J, Bock N, Villarino ME; TB Trials Consortium.

Int J Tuberc Lung Dis. 2015 Sep;19(9):1039-44, i-v. doi: 10.5588/ijtld.14.0829.

10.

Treatment for preventing tuberculosis in children and adolescents: a randomized clinical trial of a 3-month, 12-dose regimen of a combination of rifapentine and isoniazid.

Villarino ME, Scott NA, Weis SE, Weiner M, Conde MB, Jones B, Nachman S, Oliveira R, Moro RN, Shang N, Goldberg SV, Sterling TR; International Maternal Pediatric and Adolescents AIDS Clinical Trials Group; Tuberculosis Trials Consortium.

JAMA Pediatr. 2015 Mar;169(3):247-55. doi: 10.1001/jamapediatrics.2014.3158. Erratum in: JAMA Pediatr. 2015 Sep;169(9):878.

11.

Cost-effectiveness of a 12-dose regimen for treating latent tuberculous infection in the United States.

Shepardson D, Marks SM, Chesson H, Kerrigan A, Holland DP, Scott N, Tian X, Borisov AS, Shang N, Heilig CM, Sterling TR, Villarino ME, Mac Kenzie WR.

Int J Tuberc Lung Dis. 2013 Dec;17(12):1531-7. doi: 10.5588/ijtld.13.0423.

12.
13.

Assimilation of diazotrophic nitrogen into pelagic food webs.

Woodland RJ, Holland DP, Beardall J, Smith J, Scicluna T, Cook PL.

PLoS One. 2013 Jun 28;8(6):e67588. doi: 10.1371/journal.pone.0067588. Print 2013.

14.

Public health costs for tuberculosis suspects in Wake County, North Carolina, United States.

Park PH, Holland DP, Wade A, Goswami ND, Bissette D, Stout JE.

Int J Tuberc Lung Dis. 2013 Jun;17(6):759-63. doi: 10.5588/ijtld.12.0739.

PMID:
23676158
15.

Shorter drug regimens for tuberculosis: the multiple applications of decision models.

Holland DP, Sinanovic E.

Int J Tuberc Lung Dis. 2013 May;17(5):569. doi: 10.5588/ijtld.13.0204. No abstract available.

PMID:
23575318
16.

Current management options for latent tuberculosis: a review.

Norton BL, Holland DP.

Infect Drug Resist. 2012;5:163-73. doi: 10.2147/IDR.S29180. Epub 2012 Nov 29.

17.

Geographic information system-based screening for TB, HIV, and syphilis (GIS-THIS): a cross-sectional study.

Goswami ND, Hecker EJ, Vickery C, Ahearn MA, Cox GM, Holland DP, Naggie S, Piedrahita C, Mosher A, Torres Y, Norton BL, Suchindran S, Park PH, Turner D, Stout JE.

PLoS One. 2012;7(10):e46029. doi: 10.1371/journal.pone.0046029. Epub 2012 Oct 2.

18.

Effect of HIV infection on tolerability and bacteriologic outcomes of tuberculosis treatment.

Bliven-Sizemore EE, Johnson JL, Goldberg S, Burman WJ, Villarino ME, Chaisson RE; Tuberculosis Clinical Trials Consortium.

Int J Tuberc Lung Dis. 2012 Apr;16(4):473-9. doi: 10.5588/ijtld.11.0548.

PMID:
22325844
19.

Strategies for treating latent multiple-drug resistant tuberculosis: a decision analysis.

Holland DP, Sanders GD, Hamilton CD, Stout JE.

PLoS One. 2012;7(1):e30194. doi: 10.1371/journal.pone.0030194. Epub 2012 Jan 17.

20.

Three months of rifapentine and isoniazid for latent tuberculosis infection.

Sterling TR, Villarino ME, Borisov AS, Shang N, Gordin F, Bliven-Sizemore E, Hackman J, Hamilton CD, Menzies D, Kerrigan A, Weis SE, Weiner M, Wing D, Conde MB, Bozeman L, Horsburgh CR Jr, Chaisson RE; TB Trials Consortium PREVENT TB Study Team.

N Engl J Med. 2011 Dec 8;365(23):2155-66. doi: 10.1056/NEJMoa1104875.

Supplemental Content

Loading ...
Support Center